These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 3030933)

  • 1. Chemotherapy of leishmaniasis in India.
    Thakur CP
    Indian J Pediatr; 1987; 54(1):7-10. PubMed ID: 3030933
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent advances in the treatment of visceral leishmaniasis.
    Davidson RN; Croft SL
    Trans R Soc Trop Med Hyg; 1993; 87(2):130-1, 141. PubMed ID: 8393221
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of kala-azar in India.
    Thakur CP
    Natl Med J India; 1992; 5(5):203-5. PubMed ID: 1338871
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of infantile visceral leishmaniasis].
    Minodier P; Faraut-Gambarelli F; Piarroux R; Gire C; Garnier JM; Dumon H
    Arch Pediatr; 1999 Jan; 6(1):59-66. PubMed ID: 9974099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of kala azar.
    Ozsoylu S
    Lancet; 1996 Jun; 347(9016):1701. PubMed ID: 8642997
    [No Abstract]   [Full Text] [Related]  

  • 6. [Visceral leishmaniasis: new drugs].
    Minodier P; Robert S; Retornaz K; Garnier JM
    Arch Pediatr; 2003 Dec; 10 Suppl 5():550s-556s. PubMed ID: 15022780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of visceral leishmaniasis in children].
    Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
    Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kala-azar in Bihar.
    Prasad LS
    Indian J Pediatr; 1987; 54(1):103-10. PubMed ID: 3030932
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of localized cutaneous leishmaniasis].
    Buffet P; Caumes E; Gentilini M
    Ann Dermatol Venereol; 1994; 121(6-7):503-11. PubMed ID: 7702288
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.
    Kuyucu N; Kara C; Bakirtaç A; Teziç T
    Pediatr Infect Dis J; 2001 Apr; 20(4):455-7. PubMed ID: 11332679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy.
    di Martino L; Mantovani MP; Gradoni L; Gramiccia M; Guandalini S
    Trans R Soc Trop Med Hyg; 1990; 84(4):534-5. PubMed ID: 2091347
    [No Abstract]   [Full Text] [Related]  

  • 12. Visceral leishmaniasis in clinical practice.
    Davidson RN
    J Infect; 1999 Sep; 39(2):112-6. PubMed ID: 10609527
    [No Abstract]   [Full Text] [Related]  

  • 13. The chemotherapy of protozoal infections: whither?
    Steck EA
    J Protozool; 1981 Feb; 28(1):30-5. PubMed ID: 6265632
    [No Abstract]   [Full Text] [Related]  

  • 14. Relapse in Ethiopian visceral leishmaniasis (VL) patients after therapy with pentavalent antimonials: a ten year observation.
    Berhe N; Ali A; Hailu A; Yeneneh H
    Acta Trop; 1994 Jun; 57(1):83-90. PubMed ID: 7942358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
    Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
    AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renal transplant patient with visceral leishmaniasis who could not tolerate meglumine antimoniate-cure with ketoconazole and allopurinol.
    Hueso M; Bover J; Serón D; Gil-Vernet S; Rufí G; Alsina J; Grinyó JM
    Nephrol Dial Transplant; 1999 Dec; 14(12):2941-3. PubMed ID: 10570102
    [No Abstract]   [Full Text] [Related]  

  • 17. Amphotericin B in visceral leishmaniasis.
    Jha BB
    Indian Pediatr; 1996 Nov; 33(11):971. PubMed ID: 9141838
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
    Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
    Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients.
    Ribera E; Ocaña I; de Otero J; Cortes E; Gasser I; Pahissa A
    Am J Med; 1996 May; 100(5):496-501. PubMed ID: 8644760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
    Minodier P; Retornaz K; Horelt A; Garnier JM
    Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.